Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 498 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Surgical resection (standard of care) Clear all
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes

NCT03579160
View directory record Official record
Conditions
Wound of Skin, Wound Heal, Surgical Wound, Full Thickness Skin Graft Healing
Interventions
0.25% timolol gel with full-thickness skin grafts, Vaseline dressing
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 9, 2026, 4:41 AM EDT
Recruiting Not applicable Interventional

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

NCT07361874
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
Interventions
Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 9, 2026, 4:41 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2
Biological · Radiation · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
68
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 9, 2026, 4:41 AM EDT
Completed Not applicable Interventional Results available

Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

NCT01157676
View directory record Official record
Conditions
Bladder Cancer Requiring Cystectomy
Interventions
Open radical cystectomy, Robotic assisted radical cystectomy, DaVinci robot
Procedure · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Phoenix, Arizona • Orange, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 9, 2026, 4:41 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers

NCT02910726
View directory record Official record
Conditions
Pediatric Patients With Solid Tumors
Interventions
Sentinel Lymph Node Biopsy, indocyanine green (ICG)
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 30 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
New York, New York • Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 9, 2026, 4:41 AM EDT
Not yet recruiting Phase 2 Interventional

PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC

NCT07836049
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Toripalimab, Carboplatin + Paclitaxel
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 9, 2026, 4:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Indwelling vs Immediate Removal of Foley Catheter After Robotic Assisted Laparoscopic Sacrocolpopexy: a Prospective Study

NCT02765893
View directory record Official record
Conditions
Urinary Retention
Interventions
No Foley
Other
Lead sponsor
Atlantic Health System
Other
Eligibility
19 Years to 75 Years · Female only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 9, 2026, 4:41 AM EDT
Not yet recruiting Phase 3 Interventional

A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer

NCT02448173
View directory record Official record
Conditions
Stage II Colon Cancer
Interventions
OncoVAX and Surgery, Surgery
Biological · Procedure
Lead sponsor
Vaccinogen Inc
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 9, 2026, 4:41 AM EDT
Completed No phase listed Observational

Functional Imaging of Cerebellar Mutism Syndrome

NCT01733173
View directory record Official record
Conditions
Brain Mass
Interventions
MRI with DTI and fMRI
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 9, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Abbreviated Protocol for Two-Stage Exchange

NCT04662632
View directory record Official record
Conditions
Prosthetic Joint Infection
Interventions
VT-X7 Treatment System with Tobramycin Sulfate, Standard of Care, Two-stage exchange arthroplasty, VT-X7 Treatment System with Vancomycin Hydrochloride
Combination Product · Drug · Procedure
Lead sponsor
Osteal Therapeutics, Inc.
Industry
Eligibility
22 Years to 84 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • Torrance, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 9, 2026, 4:41 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

NCT04486378
View directory record Official record
Conditions
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions
RO7198457 intravenous (IV), Observational group (no intervention)
Drug · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 9, 2026, 4:41 AM EDT
Recruiting Phase 2 Interventional

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

NCT06423326
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nab-paclitaxel, Pancreatic Surgical Procedure
Procedure · Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 9, 2026, 4:41 AM EDT
Recruiting Phase 1 Interventional

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

NCT07541781
View directory record Official record
Conditions
Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma, Grade 4 Malignant Glioma of Brain (Disorder)
Interventions
Sitagliptin, Bevacizumab
Drug · Biological
Lead sponsor
Kailin Yang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 9, 2026, 4:41 AM EDT
Withdrawn Phase 2 Interventional

Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study

NCT04987281
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage I Lung Cancer AJCC v8
Interventions
Computed Tomography, Indocyanine Green Solution, Therapeutic Bronchoscopy
Procedure · Drug · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 9, 2026, 4:41 AM EDT
Terminated Phase 3 Interventional Results available

Pulmonary Rehabilitation Before Lung Cancer Resection

NCT02887521
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Chronic Obstructive Pulmonary Disease (COPD)
Interventions
education, rehabilitation, pedometer, surgery
Other · Procedure · Device
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Jacksonville, Florida • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 9, 2026, 4:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Activity Restrictions After Inguinal Hernia Repair

NCT05867134
View directory record Official record
Conditions
Inguinal Hernia
Interventions
Removal of postoperative lifting restrictions
Behavioral
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 9, 2026, 4:41 AM EDT
Active, not recruiting Phase 2 Interventional

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

NCT03092323
View directory record Official record
Conditions
Soft Tissue Sarcoma of the Extremity
Interventions
Pembrolizumab
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
12 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Jacksonville, Florida • Iowa City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 9, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Results available

MK-3475 Immunotherapy in Endometrial Carcinoma

NCT02630823
View directory record Official record
Conditions
Endometrial Cancer, Endometrial Carcinoma, Neoplasms, Endometrial
Interventions
MK-3475, Surgical resection (standard of care), Paclitaxel (standard of care), Carboplatin (standard of care), Radiation (standard of care), Endometrial biopsy, Peripheral blood draw
Drug · Procedure · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 9, 2026, 4:41 AM EDT
Completed Not applicable Interventional Results available

Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

NCT01242800
View directory record Official record
Conditions
Breast Cancer, Stage IV Breast Cancer
Interventions
palliative surgery, therapeutic conventional surgery, palliative radiation therapy, radiation therapy
Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
369
States / cities
Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 267 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 9, 2026, 4:41 AM EDT
Not listed Phase 3 Interventional

Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing

NCT02907385
View directory record Official record
Conditions
Rectal Cancer, Anastomotic Leak
Interventions
LifeSeal™ Kit
Device
Lead sponsor
LifeBond Ltd.
Industry
Eligibility
21 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
23
States / cities
Los Angeles, California • Stanford, California • Florida City, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 9, 2026, 4:41 AM EDT
Completed Phase 1 Interventional

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

NCT04323202
View directory record Official record
Conditions
Basal Cell Carcinoma of the Head and Neck
Interventions
Pembrolizumab, Tissue collection
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 9, 2026, 4:41 AM EDT
Recruiting Phase 1 Interventional

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

NCT06492954
View directory record Official record
Conditions
Osteosarcoma, Pulmonary Recurrence of Osteosarcoma
Interventions
Surgical Resection, Stereotactic Body Radiation Therapy (SBRT), Atezolizumab
Procedure · Radiation · Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 9, 2026, 4:41 AM EDT
Recruiting Phase 2 Interventional

Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER

NCT05870800
View directory record Official record
Conditions
Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
Interventions
Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 9, 2026, 4:41 AM EDT
Recruiting Phase 2 Interventional

Embryonal Tumor With Multilayered Rosettes

NCT06861244
View directory record Official record
Conditions
Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions
Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample
Radiation · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 9, 2026, 4:41 AM EDT